Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses SynCon, to help engineer precisely designed plasmid DNA plasmids, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company's lead product candidate is INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade squamous intraepithelial lesions; INO-3112 for the treatment of HPV-related Oropharyngeal squamous cell carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 2/3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. The company's partners and collaborators ApolloBio Corporation, AstraZeneca, Coherus Biosciences, Defense Advanced Research Projects Agency, HIV Vaccines Trial Network, Kaneka Eurogentec, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter BioLogics, the University of Pennsylvania, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.…
Inovio Pharmaceuticals Prepares First Product Launch After VOCERYQ FDA Approval
Inovio Pharmaceuticals (NASDAQ: INO) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 112 employees.
The shares were at 1.760 USD on 20 November 2026, down 17.0% over 52 weeks. Its 52-week range is 0.5666 USD to 2.720 USD: the price is 35.3% below the high and 210.6% above the low.
Its market capitalisation is 329.66M USD.
Inovio Pharmaceuticals reports return on equity of -352.5%.
It holds more cash than debt, a net cash position of 41.08M USD. Its Piotroski F-score is 0 out of 9, a weak reading of its financial health. 3 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 6.333 USD is 259.8% above the current price. The next earnings report is expected on 11 March 2027.